Want to see PVLA full AI Analyst Report?

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

791 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PVLA Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Palvella

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$235.40

▲(81.06% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $235.40 with a high forecast of $270.00 and a low forecast of $205.00. The average price target represents a 81.06% change from the last price of $130.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","146":"$146","271":"$271","83.5":"$83.5","208.5":"$208.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":235.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$235.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$205.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,83.5,146,208.5,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.59,124.69846153846154,136.80692307692308,148.91538461538462,161.02384615384616,173.1323076923077,185.24076923076922,197.34923076923076,209.4576923076923,221.56615384615384,233.67461538461538,245.78307692307692,257.89153846153846,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.59,122.03692307692307,131.48384615384617,140.93076923076924,150.3776923076923,159.82461538461538,169.27153846153846,178.71846153846155,188.16538461538462,197.6123076923077,207.0592307692308,216.50615384615386,225.95307692307694,{"y":235.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.59,119.69846153846154,126.80692307692308,133.91538461538462,141.02384615384616,148.1323076923077,155.24076923076922,162.34923076923076,169.4576923076923,176.56615384615384,183.67461538461538,190.78307692307692,197.89153846153846,{"y":205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.59,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$270.00

Average Price Target$235.40

Lowest Price Target$205.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Whitney Ijem

Canaccord Genuity

$227

Buy

74.60%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Tyra Bioscience (NASDAQ: TYRA) and Revolution Medicines (NASDAQ: RVMD)

Annabel Samimy

Stifel Nicolaus

$250

Buy

92.29%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

Albert Lowe

Craig-Hallum

$205

Buy

57.68%

Upside

Reiterated

06/22/26

Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Andrew Fein

H.C. Wainwright

$255→$270

Buy

107.68%

Upside

Reiterated

06/11/26

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

Graig Suvannavejh

Mizuho Securities

$240

Buy

84.60%

Upside

Reiterated

06/04/26

Mizuho Securities Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Trevor Allred

Oppenheimer

$210

Buy

61.53%

Upside

Reiterated

05/21/26

Oppenheimer Remains a Buy on Palvella Therapeutics (PVLA)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN) and Palvella Therapeutics (NASDAQ: PVLA)

Geulah Livshits

Chardan Capital

$240

Buy

84.60%

Upside

Reiterated

05/20/26

Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Sudan Loganathan

Stephens

$220

Buy

69.22%

Upside

Initiated

05/11/26

Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential

Sam Slutsky

LifeSci Capital

$225

Buy

73.06%

Upside

Assigned

05/09/26

Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), Palvella Therapeutics (NASDAQ: PVLA) and MBX Biosciences, Inc. (NASDAQ: MBX)

Ritu Baral

TD Cowen

$267

Buy

105.37%

Upside

Reiterated

05/08/26

Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)

Jeet Mukherjee

BTIG

$215

Buy

65.37%

Upside

Reiterated

04/01/26

Palvella Therapeutics (PVLA) Gets a Buy from BTIG

Kaveri Pohlman

Clear Street

$200→$220

Buy

69.22%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Catherine Novack

JonesTrading

$143→$209

Buy

60.76%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

61.53%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Whitney Ijem

Canaccord Genuity

$227

Buy

74.60%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Tyra Bioscience (NASDAQ: TYRA) and Revolution Medicines (NASDAQ: RVMD)

Annabel Samimy

Stifel Nicolaus

$250

Buy

92.29%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

Albert Lowe

Craig-Hallum

$205

Buy

57.68%

Upside

Reiterated

06/22/26

Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Andrew Fein

H.C. Wainwright

$255→$270

Buy

107.68%

Upside

Reiterated

06/11/26

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

Graig Suvannavejh

Mizuho Securities

$240

Buy

84.60%

Upside

Reiterated

06/04/26

Mizuho Securities Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Trevor Allred

Oppenheimer

$210

Buy

61.53%

Upside

Reiterated

05/21/26

Oppenheimer Remains a Buy on Palvella Therapeutics (PVLA)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN) and Palvella Therapeutics (NASDAQ: PVLA)

Geulah Livshits

Chardan Capital

$240

Buy

84.60%

Upside

Reiterated

05/20/26

Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Sudan Loganathan

Stephens

$220

Buy

69.22%

Upside

Initiated

05/11/26

Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential

Sam Slutsky

LifeSci Capital

$225

Buy

73.06%

Upside

Assigned

05/09/26

Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), Palvella Therapeutics (NASDAQ: PVLA) and MBX Biosciences, Inc. (NASDAQ: MBX)

Ritu Baral

TD Cowen

$267

Buy

105.37%

Upside

Reiterated

05/08/26

Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)

Jeet Mukherjee

BTIG

$215

Buy

65.37%

Upside

Reiterated

04/01/26

Palvella Therapeutics (PVLA) Gets a Buy from BTIG

Kaveri Pohlman

Clear Street

$200→$220

Buy

69.22%

Upside

Reiterated

03/02/26

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

Catherine Novack

JonesTrading

$143→$209

Buy

60.76%

Upside

Reiterated

02/24/26

Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

61.53%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months

Andrew FeinH.C. Wainwright

Success Rate

14/15 ratings generated profit

Average Return

+57.93%

Copying Andrew Fein's trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +57.93% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

15/15 ratings generated profit

Average Return

+243.00%

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +243.00% per trade.

2 Years

Andrew FeinH.C. Wainwright

Success Rate

15/15 ratings generated profit

Average Return

+277.39%

Copying Andrew Fein's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +277.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PVLA has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 235.40.

Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$1.16 with a range of -$1.42 to -$0.83. The previous quarter’s EPS was -$1.20. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 235.40.

What is PVLA’s upside potential, based on the analysts’ average price target?

Palvella Therapeutics, Inc. has 81.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PVLA a Buy, Sell or Hold?

Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Palvella Therapeutics, Inc.’s price target?

The average price target for Palvella Therapeutics, Inc. is 235.40. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $270.00 ,the lowest forecast is $205.00. The average price target represents 81.06% Increase from the current price of $130.01.

What do analysts say about Palvella Therapeutics, Inc.?

Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of PVLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

PVLA Analyst Ratings

PVLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Palvella Therapeutics

PVLA Analyst Recommendation Trends

PVLA Financial Forecast

PVLA Earnings Forecast

PVLA Sales Forecast

PVLA Stock Forecast FAQ

Detailed List of Analyst Forecasts